This study aims to conduct the first randomized, prospective trial to better clear up the association between early and standard follow-up on readmission rates. The investigators hypothesize that unlike heart failure or advanced valvular disease patients, the benefit of early outpatient follow-up in reducing readmission of post-MI patients will be less clear. The investigators will examine the distribution of demographic, clinical, and socioeconomic characteristic according to readmission compared to.no readmission. The investigators believe this the design and method of study could be used to answer similar questions in other subsets of patients.
This is an interventional, randomized, parallel assignment with an estimated 2000 participants. The study began in March 2014 and is expected to be completed by December 2019.
- All sexes, ages 18 and older
- Patients with acute MI (STEMI or NSTEMI) will be recruited from the PAC-CCU service and may have been admitted through the Duke Emergency Department or transferred from a referring hospital
- Clinical events and treatment during the hospitalization (e.g., medical management versus cardiac catheterization, ICU vs. non-ICU care, choice of medications, etc.) will not influence inclusion in the trial and inclusion in the trial will not influence treatment during hospitalization or during follow up, except for the timing of the follow-up appointment
- Patients discharged to skilled nursing facilities will be eligible for this study.
- Patients treated with coronary artery bypass grafting will be excluded for the purposes of this trial to avoid conflicts with usual post-operative management.
- Additionally, patients with features or clinical courses that would preclude the possibility of readmission will be excluded.
- Examples include transition of care goals to comfort care, transition of care to inpatient or outpatient hospice, or the development of complications during the hospitalization that require early follow up appointments (e.g., diagnosis of malignancy).
You may participate in this clinical trial at Duke University Medical Center in Durham, NC, 27705, United States. If you have any questions or concerns you may contact: Jennifer Rymer, MD; Phone: 919-668-8002; Email: firstname.lastname@example.org or Kristin Newby, MD; Phone: 919-668-8002; Email: email@example.com
This study is sponsored by Duke University with Kristin Newby of Duke Clinical Research Institute as the Principal Investigator.
Clinical TrialsView All
Testing a Community Intervention to Increase Aspirin Use
Recently, there is a growing consensus that aspirin, when appropriately used, reduces cardiovascular death in men,…
MRI of Myocardial Infarction
Heart failure (HF) affects approximately 5.1 million people in the US and is the cause of 250,000 deaths each year.…
Impact of Daylight on Patients With Acute Myocardial Infarction
Damage from a heart attack usually occurs during the early morning hours. Therefore, the circadian system is…
CLEAR SYNERGY Neutrophil Substudy
CLEAR SYNERGY is an international, randomized placebo controlled trial of the poisonous alkaline colchicine and…
Evaluating Vitamin D Normalization on Cardiovascular-Related Events
This study evaluates whether achieving 25-hydroxyvitamin D, or 25[OH] Vit D (what vitamin D is converted into…
Testosterone Replacement and Exercise Capacity in Hypogonadal Men
This study examines the effect of testosterone replacement on the ability to exercise for men with functional…